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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.018Mutations in the gene encoding the single transmembrane receptor multiple epidermal growth factor-
like domain 10 (MEGF10) cause an autosomal recessive congenital muscle disease in humans. Although
mammalian MEGF10 is expressed in the central nervous system as well as in skeletal muscle, patients
carrying mutations in MEGF10 do not show symptoms of central nervous system dysfunction. drpr is the
sole Drosophila homolog of the human genes MEGF10, MEGF11, and MEGF12 (JEDI, PEAR). The functional
domains of MEGF10 and drpr bear striking similarities, and residues affected by MEGF10 mutations in
humans are conserved in drpr. Our analysis of drpr mutant ﬂies revealed muscle degeneration with ﬁber
size variability and vacuolization, as well as reduced motor performance, features that have been
observed in human MEGF10 myopathy. Vacuolization was also seen in the brain. Tissue-speciﬁc RNAi
experiments demonstrated that drpr deﬁciency in muscle, but not in the brain, leads to locomotor
defects. The histological and behavioral abnormalities seen in the affected ﬂies set the stage for further
studies examining the signaling pathway modulated by MEGF10/Drpr in muscle, as well as assessing the
effects of genetic and/or pharmacological manipulations on the observed muscle defects. In addition,
the absence of functional redundancy for Drpr in Drosophila may help elucidate whether paralogs of
MEGF10 in humans (eg, MEGF11) contribute to maintaining wild-type function in the human brain.
(Am J Pathol 2014, 184: 2653e2661; http://dx.doi.org/10.1016/j.ajpath.2014.06.018)Supported by grant 186796 from the Muscular Dystrophy Association
(P.B.K.), a Boston Children’s Hospital Pilot grant (P.B.K.), and a grant
from the NIH (R01 NS080929) (P.B.K. and I.D.).
Disclosures: I.D. and P.B.K. are collaborating with Medosome Biotec,
LLC, a ﬁrm afﬁliated with the University of Florida that commercializes
scientiﬁc discoveries and have submitted a grant application to screen drug
candidates based on some of the work presented here.Muscular dystrophy is a heterogeneous group of inherited
muscle diseases characterized by persistent muscle degen-
eration and regeneration leading to muscle wasting and loss.
Recently, mutations in the gene encoding multiple epidermal
growth factorelike domain protein 10 (MEGF10) were
found to cause a novel autosomal recessive congenital
muscle disease in humans.1e3 Patients show progressive
muscle weakness with features of muscular dystrophy and
congenital myopathy.1e4MEGF10 is expressed in the central
nervous system (CNS), retina, and skeletal muscle.2,5 In the
brain, where it is abundantly expressed, MEGF10 is enriched
in astrocytes and myelinating oligodendrocytes.6 This pro-
tein has been shown to mediate engulfment of apoptotic
neurons7 as well as synapse pruning in the developing and
adult CNS8 and to participate in the uptake of amyloid-b
peptide.9 In addition, elegant studies in rodents have shown
that MEGF10, together with MEGF11, regulates the
arrangement of retinal mosaic.5 In resting muscle, MEGF10stigative Pathology.
.expression is observed in myoblasts and quiescent satellite
cells, where it suppresses the differentiation program.10
Many gaps remain, however, in our understanding of the
signaling pathway/physiological function mediated by this
receptor in muscle, as well as of the molecular consequences
of the pathogenic mutations that underlie the muscle disease
in humans. MEGF10 encodes a single-pass membrane pro-
tein with an N-terminus EMI domain followed by multiple
extracellular EGF-like domains. These structural features,
together with the intracellular noncanonical immunoreceptor
tyrosine-based activation motif (ITAM) signaling motifs,
Draper et alhave been conserved from invertebrates to humans.5,7 Pre-
vious structureefunction analyses have highlighted similar-
ities between human MEGF10 and its Drosophila (fruit ﬂy)
homolog Drpr (the corresponding gene is draper, drpr,
CG2086),7,11 raising the possibility that these proteins mediate
parallel functions. In addition to its well-characterized role in
cell corpse engulfment12 and glial response to degenerating
axons,13 Drpr mediates the remodeling of the neuromuscular
junction, where it is expressed both in glia that wrap around the
motor neurons as well as postsynaptically.14 Despite the
phylogenetic distance between Drosophila and humans, ﬂy
models of human disease have shown potential for facilitating a
better understanding of the development of the pathophysio-
logical processes that underlie neuromuscular disorders. These
include ﬂy models of spinal muscular dystrophy, lamin-
associated myopathies, actin myopathies, dystrophinopathies,
and dystroglycanopathies.15e22 The identiﬁcation of adult
muscle precursor cells in Drosophila that share features with
vertebrate satellite cells23,24 provides further rationale for using
this model organism in muscle biology investigations. This
study was designed to assess the extent to which drpr mutant
Drosophila may be used to model skeletal muscle phenotypes
with relevance to human MEGF10 myopathy. Of note,
Megf10/ mice5 do not have an obvious muscle phenotype
(Peter Kang, personal communication). The characterization of
drpr mutant and RNAi ﬂies establishes a baseline on which to
probe the signaling pathway modulated by MEGF10/Drpr in
muscle, as well as to assess the effects of genetic and/or phar-
macological manipulations on the observed muscle defects.
Materials and Methods
Drosophila Stocks and Culture
The drprD5 mutant ﬂy line [genotype: we; sp/CyOact::GFP;
drprD5rec8 (9)/TM6, sb, Tb, e; where we; sp/CyOact::GFP;
drprD5rec8 (9)/drprD5rec8 (9) null are adult viable] and UAS-
ds-drpr RNAi mutant ﬂy line (genotype: yw; UAS-
drprRNAi#7b/CyO;þ/TM6, sb, Tb, e) were gifts from Marc
R. Freeman (University of Massachusetts Medical School,
Boston, MA).12 The UAS-ds-drpr RNAi stock transformant
ID 27086 (genotype: w1118; P{GD14423}v27086,
FBst0456744) was purchased from the Vienna Drosophila
RNAi Center (Vienna, Austria). The genetic background
strain w1118 (FBal0018186) was purchased from the Bloo-
mington Drosophila Stock Center, as were the following
Gal4 driver lines: Actin5C-Gal4 (y1 w*; P{Act5C-Gal4}
25FO1/CyO, yþ; FBst0004414: ubiquitous expression),
how-Gal4 (w*; P{GawB}how24B; FBst0001767: expression
in mesoderm), Elav-Gal4 (P{GawB}elavC155; FBst0000458:
pan-neuronal expression), and twist-Gal4 (P{GAL4-twi.G}
108.4, w1; FBst0000914: expression in adult muscle pre-
cursors). The repo-Gal4 driver line (expression in glia) was a
generous gift from Mary Roberts (F. Rob Jackson laboratory,
Tufts University School of Medicine, Boston, MA). All
strains were raised at 25C in a 12-hour light/12-hour dark2654cycle on standard Drosophila media. To generate transgenic
drpr RNAi ﬂies, UAS-ds-drpr ﬂies were crossed at 29C with
ﬂies carrying the Gal4 transgene.
Assessment of Transcript Levels
RT-PCR was used to assess transcription levels of the drpr
gene. Total RNA was isolated from pooled adult male
Drosophila by RNA STAT-60 (Tel-Test, Inc., Friendswood,
TX) following the manufacturer’s recommendations. Com-
plementary cDNA was generated using MuLV Reverse
Transcriptase (Applied Biosystems Inc/Life Technologies
Corp., Grand Island, NY). Alternatively, genomic DNA was
extracted from the corresponding ﬂies and used. PCR was
performed according to standard protocols. The sequences of
the drpr locusespeciﬁc primers used for the PCR reaction
were as follows: drpr_2, forward, 50-AGGACCTGGAATC-
CACTGC-30; CG18171, reverse, 50-GCGGCAAGTAATCT-
GAGTCC-30; drpr_5, reverse, 50-GCCTGAAAAGGGCTC-
ACATA-30; drpr_5, forward, 50-CGGTATGTGAGCCCTT-
TTCA-30; drpr_6, reverse, 50-GCAGGTCATGCTGCAGTT-
30; CG12035_1, forward, 50-GCTGCTTAATATCCCCAG-
AGG-30; and CG12035_1, reverse, 50-GTCGTTACTCTT-
GGCAATGG-30.
Western Blot Analysis
Protein extraction and western blot analysis were performed
as previously reported.25 Primary antibodies were used at the
following dilutions: rabbit anti-Draper, 1:5000 (generated in
the Freeman Laboratory12); and mouse anti-Discs-Large,
1:500 (clone 4F3, Developmental Studies Hybridoma
Bank, University of Iowa, Iowa City, IA).
Lifespan Analysis
To assess lifespan, 1-day-old male adults were collected and
then regularly transferred to fresh medium every 7 days. The
number of dead ﬂies was recorded at the time of each transfer.
For the drpr heterozygous versus null lifespan study, raw
percentage survival data were collected weekly on three
populations in each group. The total numbers of ﬂies analyzed
were 83 and 70 in the heterozygous and null groups, respec-
tively. Statistical analysis on the lifespan study was performed
using a t-test in SigmaPlot version 11 software (Systat Soft-
ware Inc., Chicago, IL). Data are presented as means  SEM.
Negative Geotaxis
As an index of motor function, age-matched male adults in
the control and drpr mutant groups (n Z 10 to 12 ﬂies per
group) were examined using a negative geotaxis climbing
assay. One-day-old ﬂies were collected and maintained for 3
to 21 days in fresh vials before testing. Corresponding ﬂies
were transferred (without CO2 anesthesia) into a clear vial.
The vial was gently tapped four times to collect ﬂies at theajp.amjpathol.org - The American Journal of Pathology
Fly Model of Human MEGF10 Myopathybottom, thus prompting a negative geotaxis response. The
number of ﬂies crossing a 5-cm threshold during a 6-second
interval was recorded. Each genotype was assessed three
times consecutively. Independent groups of ﬂies/genotype
were evaluated on different days.26
Histological Analyses
Histological analyses were performed in the Department of
Pathology, Tufts Medical Center. Aged-matched (30 to 40
days old) control and drpr mutant Drosophila were
immersed in Telly’s ﬁxative for 7 days, embedded in
parafﬁn, and sectioned at 5 mm using standard techniques.
All sections were stained with hematoxylin and eosin, then
examined using standard bright-ﬁeld light microscopy.
Results
Conservation of Disease-Causing MEGF10 Mutations in
Drpr
Drpr is the Drosophila homolog of human MEGF10.
Sequence alignment (CLUSTAL 2.1) of the longest Drpr
isoform, Drpr-PE (1042 aa, http://www.ncbi.nlm.nsih.gov/Figure 1 Drpr is homologous to MEGF10. The highest degree of similarity is fou
are indicated on the right. A boxed area in the sequence denotes conservation of t
circled area in the sequence denotes lack of conservation.
The American Journal of Pathology - ajp.amjpathol.orgprotein, accession number NP_001261276.1), and human
MEGF10 protein variant a (1140 aa, http://www.ncbi.nlm.nih.
gov/protein, accession number EAW62406.1) revealed a high
degree of similarity within the EGF-like domains. The ﬂy
protein comprises 15 EGF-like domains12 versus 17 in the
human.27 Notably, within these domains, two cysteines that
are targeted by known pathogenic human gene mutations (ie,
C326R and C774R)1 are conserved inDrosophila. In contrast,
the elastin microﬁbril interface located protein (EMILIN)
domainenested arginine, which is mutated in another patient
(R71W),1 was not conserved in Drosophila (an arginine is
found in close proximity) (Figure 1). In addition to MEGF10,
Drpr also shows homology to human MEGF11 and MEGF12
[alias platelet endothelial aggregation receptor 1 (PEAR1)/
Jedi], with approximately 40% identity found in the region
encompassing the EGF-like domains.Effects of drprD5 Mutant Allele on the Expression of
drpr and on the Other Two Open Reading Frames
Nested within the Locus
TheDrosophila drpr/CG2086gene is localized on chromosome
3 (cytolocation 3L:1715595.. 731107). Recent annotationnd within the EGF-like domains (gray). Residues that are mutated in disease
he wild-type residue between the ﬂy and human counterparts. In contrast, a
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Figure 2 Molecular characterization of the drprD5 lesion in mutant ﬂies.
A: Schematic representation of the drpr gene locus (chromosome 3), adapted
from FlyBase. Noncoding (dark gray) and coding (white/light gray) exons
appear as boxes. CG18171 and CG12035 are two genes nested within the drpr
locus. The arrows indicate PCR primers. B: PCR analysis of genomic DNA and
cDNA reveals that the D5 lesion disrupts transcription of the drpr gene (as-
terisks). The two other genes, that is, CG12035 and CG18171, are not affected
by theD5 deletion. C:Western blot analysis conﬁrms that drprD5 homozygous
mutants do not produce Drpr. Cont, control (w1118) ﬂies; drpr/, drprD5
homozygous (null) mutants; drpre/þ, drprD5 heterozygous mutants.
Figure 3 drprD5 Homozygous mutants display reduced lifespan, as well
as a rapid and age-dependent decline in locomotor activity (versus het-
erozygotes). A: drprD5 Homozygous (null) ﬂies display reduced lifespan
compared with corresponding drprD5 heterozygous (het) ﬂies. One-day-old
adult male ﬂies were collected. Every 7 days, the ﬂies were transferred to
fresh food; the number of dead ﬂies was recorded at the time of transfer.
Two independent groups of each genotype were assessed. B: drpr Null ﬂies
(drpr/) show reduced climbing performance compared with correspond-
ing drprD5 heterozygous (drpr/þ) ﬂies. Locomotor function in 3- or 7-day-
old ﬂies was assessed using a negative geotaxis assay. The number of ﬂies
that could reach 5-cm threshold in a 6-second period was recorded. Each
genotype was assayed three times consecutively when the group reached
the indicated age. The assay was repeated three times by alternating ge-
notypes. Two groups of drpr/ ﬂies were assessed (the ﬂies had emerged
in different stock bottles). Data are expressed as the percentage surviving
as a function of time (in weeks) (A); data are expressed as means  SD of
nine data points (B). n Z 30 to 39 ﬂies per genotype (A); n Z 11 or 12
ﬂies per genotype (B).
Draper et alupdates of theDrosophila genome have revealed that within the
drpr locus two additional genes of unknown function are found:
CG18171 in cis- (ie, same strand) and CG12035 in trans- (ie,
opposite strand) (Figure 2A). The D5 drpr mutant allele is a
deletion that was generated by imprecise excision of the EP(3)
522 P-element inserted in the 50 untranslated region of the drpr
gene.12 Correspondingmutantﬂies are commonly used to study
the function of drpr. To assess whether the molecularD5 lesion
affects the expression of the two other genes nested in the drpr
locus, PCR primers were designed to amplify selected exons
within this region. PCR analysis of genomic DNA as well as
cDNA revealed that the drprD5 lesion disrupts transcription of
the drpr gene but did not affect the other two genes in the locus
(Figure 2B). Western blot analysis conﬁrmed that D5 homo-
zygotes did not produce Drpr, using a polyclonal antibody
directed against the intracellular domain of the protein, common
to all Drpr isoforms, as previously reported12,25 (Figure 2C).
Effects of drpr Null Mutant Display on Lifespan
drprD5 homozygous null ﬂies were viable into adulthood.
However, lifespan analyses demonstrated that these mutants
displayed a signiﬁcantly reduced median lifespan versus
corresponding heterozygotes (drprD5 homozygous mutants
versus drprD5 heterozygotes, approximately 6 weeks versus
8 weeks; P Z 0.014) (Figure 3).
Regulation of the Locomotor Activity of the Fly by Drpr
Expression in Muscle Versus Nervous System
To investigate whether reduced Drpr levels affect motor
function, drprD5 null mutant ﬂies were assessed using an2656established negative geotaxis assay.26 Using this approach, a
signiﬁcant decrease in performance of drprD5 mutants was
demonstrated versus that in corresponding control ﬂies
(Figure 3). The impaired motor function was readily
noticeable in drpr null mutants, which often display
abnormal position of the legs and showed a rapid age-
dependent decline in locomotor activity from 3 days to 7
to 10 days of life compared with age-matched controls
(Figure 3 and Supplemental Figure S1).
To dissect the cellular requirement that underlies the
observed motor phenotype, RNA-interference ﬂies were
generated in which drpr gene expression is down-regulated in
a tissue-speciﬁc manner (using the well-characterized Gal4/
UAS bipartite system28). RNAi ﬂies that down-regulate drpr
in the entire organism (genotype Actin5C-Gal4; UAS-ds drpr,
using the ubiquitous cytosolic actin5C-Gal4 driver line) also
displayed altered locomotor function (25-day-old ﬂies versus
age-matched controls) (data not shown). The locomotorajp.amjpathol.org - The American Journal of Pathology
Fly Model of Human MEGF10 Myopathyphenotype was recapitulated when drprRNA interference was
either induced in the mesoderm (how-Gal4 driver), or in the
adult muscle precursor cells, which express the twist tran-
scription factor (twist-Gal4 driver) (Figure 4). Conﬁrming a
muscle-speciﬁc effect, the locomotor phenotype was not
recapitulated in ﬂies that down-regulate drpr in neurons (pan-
neuronal effect using the Elav-Gal4 driver, Elav encodes a
neuronal RNA-binding protein), or in glia (using repo-Gal4
driver, repo encodes a glial-speciﬁc homeodomain protein)
(Figure 4).
Time to Abnormalities in Thoracic Muscle Morphology,
Nervous System, and Retina in Adult Drpr Mutant Flies
Assessment of the locomotor activity of the ﬂies was
complemented by histological examination of drprD5 adultFigure 4 Down-regulation of drpr in muscle cell progenitors (twist-positive cel
in adult Drosophila. A: Generation of drpr RNAi ﬂies. Crossing UAS-drpr RNAi trans
double-transgenic RNAi ﬂies. These ﬂies express double-stranded (U-shaped) drpr
targeted tissue/cell type. B: Locomotor function assessment using a negative g
6-second period was recorded. RNAi ﬂies that down-regulate drpr in muscle ce
performance that progresses with age (compared with corresponding w1118/twist-G
drpr RNAi ﬂies) display normal locomotor activity versus corresponding w1118; rep
(B). n Z 8 to 13 ﬂies per genotype (B).
The American Journal of Pathology - ajp.amjpathol.orgmale Drosophila. Flies that were 30 to 40 days old were
compared to age-matched controls. Histological analyses of
drpr null mutants revealed pathological changes in the
skeletal muscles of the thorax. The defect, which includes
hyalinization with loss of striation, variability in ﬁber size,
as well as vacuolization, primarily affected the tergal
depressor of the trochanter (jump muscle, composed of
skeletal tubular ﬁbers). In contrast, the ﬂight muscles (which
are composed of skeletal ﬁbrillar ﬁbers) appeared normal
(Figure 5). The muscle phenotype was recapitulated in drpr
RNAi ﬂies that down-regulate drpr ubiquitously (genotype
Actin5C-Gal4; UAS-ds drpr). Penetrance of the muscle
defect was low to moderate in both drprD5 homozygotes
and drpr RNAi ﬂies (approximately 10%e20%). Parallel
abnormalities were not observed in age-matched corre-
sponding control ﬂies (drprD5 heterozygotes, and w1118;ls), but not in glia (repo-positive cells), leads to reduced locomotor activity
genic ﬂies with ﬂies expressing GAL4 in a tissue-speciﬁc manner results in
RNA, leading to reduction/depletion of the endogenous drpr mRNA in the
eotaxis assay. The number of ﬂies that could reach 5-cm threshold in a
ll precursors (twist-Gal4; UAS-drpr RNAi ﬂies) show a decline in climbing
al4 control ﬂies). RNAi ﬂies that down-regulate drpr in glia (repo-Gal4; UAS-
o-Gal4 control ﬂies. Data are expressed as means  SD of nine data points
2657
Figure 5 drpr Mutant Drosophila display abnormal muscle on histological examination, as well as brain and retinal degeneration. Histological sections from
age-matched drpr mutant and control ﬂies, stained with hematoxylin and eosin. A: Analysis of drpr mutants reveals foci of pathological muscular tissue
affecting the thoracic muscles (solid arrows). Top panels: left, head, thorax, and upper abdomen of the organism; right, magniﬁcation of the tergal depressor
of the trochanter (jump muscle) shows vacuolized ﬁbers. Bottom panels: longitudinal section (left) and cross section (right) of affected muscles showing
additional abnormalities (ie, loss of striation, loss of nuclei, enlarged ﬁber; solid arrows) in the vicinity of normal striated ﬁbers (dashed arrow). B: Analysis
of drpr mutants reveals extensive vacuolization in the brain, ventral nerve cord, and optic lobes. Left panels: Normal brain (top, dashed line), ventral nerve
cord (top, arrow), and retina (bottom) are shown. Right panels: widespread vacuolization/degeneration is seen in the brain (solid line), the ventral nerve
cord (arrow), and the optic lobe (arrowheads) of drpr mutant ﬂies. Of note, comparable muscle and brain abnormalities were observed in drprD5 homozygotes
(drpr null ﬂies) and drpr RNAi ﬂies; these defects were absent in control ﬂies (comparison of the brain defects is shown in Supplemental Figure S2). The
different groups of ﬂies were: 30-day-old drprD5 homozygotes [drpr nulls: we; sp/CyOact::GFP; drprD5rec8 (9)/drprD5rec8 (9)], 40-day-old drpr RNAi ﬂies (we,
Act5C-Gal4/UAS-ds drpr RNAi, leading to down-regulation of drpr in the entire organism), and 40-day-old control ﬂies (we, Act5C-Gal4).
Draper et alActin5C-Gal4, respectively). In addition, marked degener-
ation was readily observed in the nervous systems of adult
drprD5 mutant ﬂies as well as in drpr RNAi ﬂies, both
within the brain and in the thoracic ventral ganglion
(Figure 5 and Supplemental Figure S2). Many vacuoles
were seen, which clustered on the ventral part of the nervous
system. Degeneration of the visual center was also evident
in drpr mutant ﬂies in which alterations were seen in the
retina and within the optic ganglia (ie, lamina, medulla)
(Figure 5). The brain/retinal phenotype was highly penetrant
(100% adult ﬂies were affected, with individual variability
in the degree of severity).Discussion
The clinical and pathological features associated with the rare
MEGF10 myopathy vary broadly, depending on the speciﬁc
mutation. Missense mutations have been shown to result in a
mild neuromuscular phenotype with prolonged preservation
of ambulation,1 whereas frameshift mutations leading to2658nonsense-mediated mRNA decay (null mutations) cause the
more severe early onset myopathy, areﬂexia, respiratory
distress, and dysphagia (EMARDD) phenotype, which in-
volves diaphragmatic paralysis requiring continuous respira-
tory assistance.2,3 One severe missense mutation impairs
tyrosine phosphorylation more than does a milder missense
mutation in vitro, offering a potential explanation for the
phenotypic variability.29 The corresponding histological an-
alyses of the muscles show characteristics that are common to
all forms of the disease (fatty tissue replacement of the mus-
cle), as well as features that have to date been described only
in the milder form (moth-eaten ﬁbers/minicores, occasional
regenerating ﬁbers).1,2 Muscle magnetic resonance imaging
in a patient carrying the null mutation has facilitated visuali-
zation of the extensive fatty replacement of the proximal
muscles.3 MEGF10 plays a role in the proliferation of Pax7-
positive satellite cells and in muscle regeneration.10 Pax7-
positive satellite cells were found to be absent in the muscle
tissue of one EMARDD patient.2
To further understand MEGF10-mediated function in
muscle, we used Drosophila as a model organism. Fliesajp.amjpathol.org - The American Journal of Pathology
Fly Model of Human MEGF10 Myopathyprovide a unique opportunity to expand corresponding
studies: i) the ﬂy homolog of MEGF10, Drpr, shows con-
servation of the structurally and functionally important
cysteines that are targeted by human mutations,30 ii) pre-
viously generated drpr null mutants are viable,12 enabling
characterization of the knockout phenotype in ﬂy muscles,
iii) the Gal4/UAS bipartite system28 enables genetic
manipulation of Drpr expression in a tissue-speciﬁc manner
(eg, muscle progenitors), and iv) similar expression patterns
of ﬂy Drpr and mammalian MEGF10 have been reported in
mature muscle ﬁbers (at the postsynaptic membrane of the
neuromuscular junction2,14). In addition, Drpr is the sole
homolog of mammalian MEGF10, MEGF11, and MEGF12,
thus eliminating, in Drosophila, possible functional redun-
dancy of paralogs and providing insight into the role of this
family of transmembrane proteins in different tissues.
drpr null mutant ﬂies [genotype we; sp/CyOact::GFP;
drprD5rec8 (9)/drprD5rec8 (9)] display a shortened lifespan
(Figure 3), and an age-dependent locomotor defect (versus
heterozygotes) that is noticeable starting at approximately 2
weeks of age. The motor phenotype is readily quantiﬁed in
behavioral assays and often is associated with an abnormal
positioning of the legs (eg, a rigid limb that is either held
upright or drags). The motor defect is also observed when
drpr expression is down-regulated in a different genetic
background (drpr RNAi ﬂies). This phenotype offers a
potential means to identify pharmacological modiﬁers of the
MEGF10/Drpr depletioneinduced muscle defect, using the
ﬂy model in medium throughput screens. Notably, ﬂy
models of other human muscle diseases (oculopharyngeal
muscular dystrophy, myotonic dystrophy type 1) have been
used successfully to establish in vivo platforms for identi-
fying potential therapeutic compounds.31
In contrast to the human phenotype, in which only skel-
etal muscle alterations have been reported, histopathological
examination of drpr knockout and RNAi ﬂies reveals
marked defects in the muscles as well as in the CNS (brain
hemispheres, ventral cord, and retina). Vacuole formation is
observed across all affected ﬂy tissues. In muscles these
lesions may be the result of fat inﬁltration, a feature that is
widespread in human EMARDD biopsies. Well-deﬁned
vacuoles have also been observed in a limited number of
other Drosophila models of muscle disease, including
oculopharyngeal muscular dystrophy and myotonic dystro-
phy type 1.26,32e34 Further studies in this group of selected
ﬂy models may enable the dissection of the molecular
processes that result in vacuolization and fat deposition in
degenerating muscle. In addition, vacuolization has been
described as a distinctive feature in the brain of numerous
ﬂy models of neurodegenerative disease.35
The brain lesions are reminiscent of those described in
Drosophila Swiss cheese (sws) mutants. sws Is expressed in
neurons and in a subset of glial cells that encode an
evolutionarily conserved protein with lysophospholipase
activity.35e37 In these mutants, hyperwrapping of neurons
by glial sheaths precedes vacuole formation. It thus appearsThe American Journal of Pathology - ajp.amjpathol.orgthat in Drosophila, mutations in either drpr or sws, two
genes that have a role in neuroneglia communication and
the engulfment of apoptotic neurons,13,37 result in the
development of brain lesions with similar histopathological
features.
Sws and its mammalian homolog neuropathy target
esterase possess phospholipase activity and regulate the
metabolism of membrane-associated lipids, including lyso-
phosphatidylcholine and phosphatidylcholine (PC).38,39
Mutations in sws lead to increased levels of cellular PC.37
Altered levels of PC/lysophosphatidylcholine have been
associated with membrane breakdown and the development
of neurodegenerative disease.40 Lysophosphatidylcholine is
also a known bioactive signaling factor that acts as a ﬁnd me
and eat me signal when produced in apoptotic cells.41
Intriguingly, it was recently shown that another classic eat
me phospholipid signal, that is, phospatidylserine, is a
ligand for the Drpr receptor and regulates Drpr-mediated
clearance of apoptotic neurons.8,42 Parallels in humans
may be proposed, and it is possible that either phospati-
dylserine or PC, the levels of which increase in response to
A-b1e40 accumulation,
43 regulates MEGF10-mediated
removal of the b-amyloid peptide.9
In muscle, in vitro studies performed in C2C12 cells have
shown that selected lysophospholipids stimulated the pro-
liferation, and inhibited the differentiation, of myoblasts.44
These effects are reminiscent of those induced by MEGF10
overexpression in the same cell type.10 More recently, studies
in vivo have demonstrated a beneﬁcial effect of lysophos-
pholipids on muscle function; in mice, sphingosine 1 phos-
phate (S1P) promoted the regeneration of injured mdx
muscle45 and in Drosophila S1P attenuated the development
of dystrophic muscle alterations.46 Conversely, in humans,
mutations in the choline kinase beta gene (CHKB) resulted in
altered biosynthesis of PC, causing a form of congenital
muscular dystrophy.29 The potential relevance of these
bioactive/signaling factors as mediators of MEGF10/Drpr-
dependent physiology in muscle remains to be explored.
Notably, the brain degeneration observed in Drpr-deﬁcient
ﬂies (in addition to abnormalities in muscle) contrasted with
the human phenotype, which affected only skeletal muscle.
Myopathic patients carrying mutations in MEGF10 had
normal brain imaging and did not show symptoms of CNS
dysfunction.1,4 It is possible that in mammals, functional
redundancy between MEG10 and its paralogs MEGF11 and
MEGF12 contribute to maintaining normal brain function in
MEGF10 myopathy. Consistent with this hypothesis is the
recent study showing no gross phenotypic abnormalities in
either themegf10/ ormegf11/ knockout mouse; however,
the corresponding double-knockout mouse had markedly
disrupted retinas.5 The absence of functional redundancy for
Drpr in Drosophila may help to elucidate whether MEGF11
and/or MEGF12 in humans prevents nervous system degen-
eration in patients bearing a MEGF10 mutation. Mammalian
genes may be introduced in the ﬂy background not only to
study the in vivo function of the wild-type protein but also to2659
Draper et alinvestigate the effects of naturally occurring variants (splice
variants, mutant isoforms, deletions).16,19,21,32,47 In the
absence of other available in vivo assays, this approach is
particularly helpful when investigating whether novel muta-
tions found in a human muscular dystrophy gene (eg, LMNA)
may be pathogenic.16 Drosophila thus provides a useful
framework for pursuing structureefunction analyses of
important regulators of muscle physiology. A potential future
direction for study could involve the introduction of the
mammalian MEGF10, MEGF11, and MEGF12 cDNAs into
the ﬂy mutant background to examine the in vivo function of
the corresponding proteins and the effects of mutations.
Acknowledgments
We thank Marc R. Freeman (University of Massachusetts
Medical School, Worcester, MA) for the generous gift of the
drprD5 mutant ﬂy line, the UAS-ds-drpr RNAi mutant ﬂy
line, and the polyclonal anti-Drpr antibody; Ci Chen for
excellent technical assistance; and Elicia Estrella for helpful
discussions.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2014.06.018.
References
1. Boyden SE, Mahoney LJ, Kawahara G, Myers JA, Mitsuhashi S,
Estrella EA, Duncan AR, Dey F, DeChene ET, Blasko-Goehringer JM,
Bönnemann CG, Darras BT, Mendell JR, Lidov HG, Nishino I,
Beggs AH, Kunkel LM, Kang PB: Mutations in the satellite cell gene
MEGF10 cause a recessive congenital myopathy with minicores.
Neurogenetics 2012, 13:115e124
2. Logan CV, Lucke B, Pottinger C, Abdelhamed ZA, Parry DA,
Szymanska K, Diggle CP, van Riesen A, Morgan JE, Markham G,
Ellis I, Manzur AY, Markham AF, Shires M, Helliwell T, Scoto M,
Hubner C, Bonthron DT, Taylor GR, Sheridan E, Muntoni F, Carr IM,
Schuelke M, Johnson CA: Mutations in megf10, a regulator of satellite
cell myogenesis, cause early onset myopathy, areﬂexia, respiratory
distress and dysphagia (EMARDD). Nat Genet 2011, 43:1189e1192
3. Pierson TM, Markello T, Accardi J, Wolfe L, Adams D, Sincan M,
Tarazi NM, Fajardo KF, Cherukuri PF, Bajraktari I, Meilleur KG,
Donkervoort S, Jain M, Hu Y, Lehky TJ, Cruz P, Mullikin JC,
Bonnemann C, Gahl WA, Boerkoel CF, Tifft CJ: Novel SNP array
analysis and exome sequencing detect a homozygous exon 7 deletion
of MEGF10 causing early onset myopathy, areﬂexia, respiratory
distress and dysphagia (EMARDD). Neuromuscul Disord 2013, 23:
483e488
4. Hartley L, Kinali M, Knight R, Mercuri E, Hubner C, Bertini E,
Manzur AY, Jimenez-Mallebrera C, Sewry CA, Muntoni F: A
congenital myopathy with diaphragmatic weakness not linked to the
SMARD1 locus. Neuromuscul Disord 2007, 17:174e179
5. Kay JN, Chu MW, Sanes JR: MEGF10 AND MEGF11 mediate
homotypic interactions required for mosaic spacing of retinal neurons.
Nature 2012, 483:465e469
6. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL,
Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA,
Thompson WJ, Barres BA: A transcriptome database for astrocytes,2660neurons, and oligodendrocytes: a new resource for understanding brain
development and function. J Neurosci 2008, 28:264e278
7. Scheib JL, Sullivan CS, Carter BD: Jedi-1 and MEGF10 signal
engulfment of apoptotic neurons through the tyrosine kinase Syk. J
Neurosci 2012, 32:13022e13031
8. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A,
Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, Smith SJ,
Barres BA: Astrocytes mediate synapse elimination through MEGF10
and MERTK pathways. Nature 2013, 504:394e400
9. Singh TD, Park SY, Bae JS, Yun Y, Bae YC, Park RW, Kim IS:
MEGF10 functions as a receptor for the uptake of amyloid-b. FEBS
Lett 2010, 584:3936e3942
10. Holterman CE, Le Grand F, Kuang S, Seale P, Rudnicki MA: Megf10
regulates the progression of the satellite cell myogenic program. J Cell
Biol 2007, 179:911e922
11. Ziegenfuss JS, Biswas R, Avery MA, Hong K, Sheehan AE,
Yeung YG, Stanley ER, Freeman MR: Draper-dependent glial
phagocytic activity is mediated by Src and Syk family kinase signal-
ling. Nature 2008, 453:935e939
12. Freeman MR, Delrow J, Kim J, Johnson E, Doe CQ: Unwrapping glial
biology: Gcm target genes regulating glial development, diversiﬁca-
tion, and function. Neuron 2003, 38:567e580
13. MacDonald JM, Beach MG, Porpiglia E, Sheehan AE, Watts RJ,
Freeman MR: The Drosophila cell corpse engulfment receptor Draper
mediates glial clearance of severed axons. Neuron 2006, 50:869e881
14. Fuentes-Medel Y, Logan MA, Ashley J, Ataman B, Budnik V,
Freeman MR: Glia and muscle sculpt neuromuscular arbors by
engulﬁng destabilized synaptic boutons and shed presynaptic debris.
PLoS Biol 2009, 7:e1000184
15. Chang HC, Dimlich DN, Yokokura T, Mukherjee A, Kankel MW,
Sen A, Sridhar V, Fulga TA, Hart AC, Van Vactor D, Artavanis-
Tsakonas S: Modeling spinal muscular atrophy in Drosophila. PLoS
One 2008, 3:e3209
16. Dialynas G, Flannery KM, Zirbel LN, Nagy PL, Mathews KD,
Moore SA, Wallrath LL: LMNA variants cause cytoplasmic distribu-
tion of nuclear pore proteins in Drosophila and human muscle. Hum
Mol Genet 2012, 21:1544e1556
17. Goldstein JA, Kelly SM, LoPresti PP, Heydemann A, Earley JU,
Ferguson EL, Wolf MJ, McNally EM: SMAD signaling drives heart
and muscle dysfunction in a Drosophila model of muscular dystrophy.
Hum Mol Genet 2011, 20:894e904
18. Rajendra TK, Gonsalvez GB, Walker MP, Shpargel KB, Salz HK,
Matera AG: A Drosophila melanogaster model of spinal muscular at-
rophy reveals a function for SMN in striated muscle. J Cell Biol 2007,
176:831e841
19. Sevdali M, Kumar V, Peckham M, Sparrow J: Human congenital
myopathy actin mutants cause myopathy and alter Z-disc structure in
Drosophila ﬂight muscle. Neuromuscul Disord 2013, 23:243e255
20. Shcherbata HR, Yatsenko AS, Patterson L, Sood VD, Nudel U, Yaffe D,
Baker D, Ruohola-Baker H: Dissecting muscle and neuronal disorders in a
Drosophila model of muscular dystrophy. EMBO J 2007, 26:481e493
21. Taghli-Lamallem O, Akasaka T, Hogg G, Nudel U, Yaffe D,
Chamberlain JS, Ocorr K, Bodmer R: Dystrophin deﬁciency in
Drosophila reduces lifespan and causes a dilated cardiomyopathy
phenotype. Aging Cell 2008, 7:237e249
22. Wairkar YP, Fradkin LG, Noordermeer JN, DiAntonio A: Synaptic
defects in a Drosophila model of congenital muscular dystrophy. J
Neurosci 2008, 28:3781e3789
23. Figeac N, Jagla T, Aradhya R, Da Ponte JP, Jagla K: Drosophila adult
muscle precursors form a network of interconnected cells and are
speciﬁed by the rhomboid-triggered EGF pathway. Development 2010,
137:1965e1973
24. Maqbool T, Jagla K: Genetic control of muscle development: learning
from Drosophila. J Muscle Res Cell Motil 2007, 28:397e407
25. McPhee CK, Logan MA, Freeman MR, Baehrecke EH: Activation of
autophagy during cell death requires the engulfment receptor Draper.
Nature 2010, 465:1093e1096ajp.amjpathol.org - The American Journal of Pathology
Fly Model of Human MEGF10 Myopathy26. Draper I, Tabaka ME, Jackson FR, Salomon RN, Kopin AS: The
evolutionarily conserved RNA binding protein SMOOTH is essential
for maintaining normal muscle function. Fly (Austin) 2009, 3:
235e246
27. Nagase T, Kikuno R, Ohara O: Prediction of the coding sequences of
unidentiﬁed human genes. XXII. The complete sequences of 50 new
cDNA clones which code for large proteins. DNA Res 2001, 8:
319e327
28. Brand AH, Perrimon N: Targeted gene expression as a means of
altering cell fates and generating dominant phenotypes. Development
1993, 118:401e415
29. Mitsuhashi S, Ohkuma A, Talim B, Karahashi M, Koumura T,
Aoyama C, Kurihara M, Quinlivan R, Sewry C, Mitsuhashi H, Goto K,
Koksal B, Kale G, Ikeda K, Taguchi R, Noguchi S, Hayashi YK,
Nonaka I, Sher RB, Sugimoto H, Nakagawa Y, Cox GA, Topaloglu H,
Nishino I: A congenital muscular dystrophy with mitochondrial
structural abnormalities caused by defective de novo phosphatidyl-
choline biosynthesis. Am J Hum Genet 2011, 88:845e851
30. Mitsuhashi S, Mitsuhashi H, Alexander MS, Sugimoto H, Kang PB:
Cysteine mutations cause defective tyrosine phosphorylation in
MEGF10 myopathy. FEBS Lett 2013, 587:2952e2957
31. Draper I: Model organisms offer new possibilities for discovery of
therapeutics. Drug Discov Today Technol 2013, 10:e61ee64
32. Chartier A, Benoit B, Simonelig M: A Drosophila model of oculo-
pharyngeal muscular dystrophy reveals intrinsic toxicity of pabpn1.
EMBO J 2006, 25:2253e2262
33. de Haro M, Al-Ramahi I, De Gouyon B, Ukani L, Rosa A,
Faustino NA, Ashizawa T, Cooper TA, Botas J: MBNL1 and
CUGBP1 modify expanded CUG-induced toxicity in a Drosophila
model of myotonic dystrophy type 1. Hum Mol Genet 2006, 15:
2138e2145
34. Garcia-Lopez A, Monferrer L, Garcia-Alcover I, Vicente-Crespo M,
Alvarez-Abril MC, Artero RD: Genetic and chemical modiﬁers of a
CUG toxicity model in Drosophila. PLoS One 2008, 3:e1595
35. Kretzschmar D: Swiss cheese et allii, some of the ﬁrst neurodegener-
ative mutants isolated in Drosophila. J Neurogenet 2009, 23:34e41
36. Kretzschmar D, Hasan G, Sharma S, Heisenberg M, Benzer S: The
Swiss cheese mutant causes glial hyperwrapping and brain degenera-
tion in Drosophila. J Neurosci 1997, 17:7425e7432The American Journal of Pathology - ajp.amjpathol.org37. Mühlig-Versen M, da Cruz AB, Tschäpe JA, Moser M, Büttner R,
Athenstaedt K, Glynn P, Kretzschmar D: Loss of Swiss cheese/neur-
opathy target esterase activity causes disruption of phosphatidylcholine
homeostasis and neuronal and glial death in adult Drosophila. J Neu-
rosci 2005, 25:2865e2873
38. Kienesberger PC, Lass A, Preiss-Landl K, Wolinski H, Kohlwein SD,
Zimmermann R, Zechner R: Identiﬁcation of an insulin-regulated
lysophospholipase with homology to neuropathy target esterase. J
Biol Chem 2008, 283:5908e5917
39. van Tienhoven M, Atkins J, Li Y, Glynn P: Human neuropathy target
esterase catalyzes hydrolysis of membrane lipids. J Biol Chem 2002,
277:20942e20948
40. Klein J: Membrane breakdown in acute and chronic neuro-
degeneration: focus on choline-containing phospholipids. J Neural
Transm 2000, 107:1027e1063
41. Hochreiter-Hufford A, Ravichandran KS: Clearing the dead: apoptotic
cell sensing, recognition, engulfment, and digestion. Cold Spring Harb
Perspect Biol 2013, 5:a008748
42. Tung TT, Nagaosa K, Fujita Y, Kita A, Mori H, Okada R, Nonaka S,
Nakanishi Y: Phosphatidylserine recognition and induction of
apoptotic cell clearance by Drosophila engulfment receptor Draper. J
Biochem 2013, 153:483e491
43. Koudinova NV, Koudinov AR, Yavin E: Alzheimer’s Abeta1-40
peptide modulates lipid synthesis in neuronal cultures and intact rat
fetal brain under normoxic and oxidative stress conditions. Neurochem
Res 2000, 25:653e660
44. Yoshida S, Fujisawa-Sehara A, Taki T, Arai K, Nabeshima Y: Lyso-
phosphatidic acid and bfgf control different modes in proliferating
myoblasts. J Cell Biol 1996, 132:181e193
45. Ieronimakis N, Pantoja M, Hays AL, Dosey TL, Qi J, Fischer KA,
Hoofnagle AN, Sadilek M, Chamberlain JS, Ruohola-Baker H,
Reyes M: Increased sphingosine-1-phosphate improves muscle
regeneration in acutely injured mdx mice. Skelet Muscle 2013, 3:20
46. Pantoja M, Fischer KA, Ieronimakis N, Reyes M, Ruohola-Baker H:
Genetic elevation of sphingosine 1-phosphate suppresses dystrophic
muscle phenotypes in Drosophila. Development 2013, 140:136e146
47. Wolf MJ, Amrein H, Izatt JA, Choma MA, Reedy MC, Rockman HA:
Drosophila as a model for the identiﬁcation of genes causing adult human
heart disease. Proc Natl Acad Sci U S A 2006, 103:1394e13992661
